Announcement in accordance with section 17 para. 2 of the General Terms and Conditions of Deutsche Börse AG for the Regulated Unofficial Market on the Frankfurt Stock Exchange
Berlin - MagForce Nanotechnologies AG, a medical technology company listed in the Entry Standard segment of the Frankfurt Stock Exchange, completed a placement of equity with German and international institutional investors. A total of 80,190 newly issued shares were placed, with profit participation rights dating from January 1, 2009, at a price of EUR 42.00 per share. The gross proceeds from this capital increase of EUR 3,367,980.00 will go to the company and are to be used to finance its further growth.
This transaction increases the nominal capital of the company, until now EUR 3,773,198.00 divided into 3,773,198 shares at an imputed nominal value of EUR 1.00, by an amount of EUR 80,190.00, thus bringing its nominal capital to EUR 3,853,388.00. Subscription rights to existing shareholders were excluded by the authority under sec. 6 para. 3 of the company’s articles of incorporation (Satzung).
About MagForce Nanotechnologies:
MagForce Nanotechnologies AG is a world-leading company in the area of nanotechnology-based cancer treatment. Its patented Nano-Cancer® therapy enables the targeted destruction of tumors using superparamagnetic nanoparticles to generate heat. The nanotechnology from MagForce represents a revolutionary approach to the future successful treatment of solid tumors.
Disclaimer:
This release may contain forward-looking statements and information which may be identified by formulations using terms such as “expects”, “aims”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or “will”. Such forward-looking statements are based on our current expectations and certain assumptions which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce Nanotechnologies AG may substantially differ from these forward-looking statements. MagForce Nanotechnologies AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated.
|
